BRPI9807076B8 - "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" - Google Patents

"uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"

Info

Publication number
BRPI9807076B8
BRPI9807076B8 BRPI9807076A BR9807076A BRPI9807076B8 BR PI9807076 B8 BRPI9807076 B8 BR PI9807076B8 BR PI9807076 A BRPI9807076 A BR PI9807076A BR 9807076 A BR9807076 A BR 9807076A BR PI9807076 B8 BRPI9807076 B8 BR PI9807076B8
Authority
BR
Brazil
Prior art keywords
treatment
multiple sclerosis
medicine
manufacture
pharmaceutical composition
Prior art date
Application number
BRPI9807076A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9807076B1 (pt
BR9807076A (pt
Inventor
Gilbert Adrian
Teitelbaum Dvora
Sela Michael
Linenberg Milka
Arnon Ruth
Riven Kreitman Rvka
Original Assignee
Yeda Reserach And Dev Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Reserach And Dev Co Ltd filed Critical Yeda Reserach And Dev Co Ltd
Publication of BR9807076A publication Critical patent/BR9807076A/pt
Publication of BR9807076B1 publication Critical patent/BR9807076B1/pt
Publication of BRPI9807076B8 publication Critical patent/BRPI9807076B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)
BRPI9807076A 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica" BRPI9807076B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11998997A IL119989A0 (en) 1997-01-10 1997-01-10 Pharmaceutical compositions for oral treatment of multiple sclerosis
PCT/US1998/000375 WO1998030227A1 (en) 1997-01-10 1998-01-12 Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Publications (3)

Publication Number Publication Date
BR9807076A BR9807076A (pt) 2000-05-02
BR9807076B1 BR9807076B1 (pt) 2013-10-29
BRPI9807076B8 true BRPI9807076B8 (pt) 2021-05-25

Family

ID=11069682

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9807076A BRPI9807076B8 (pt) 1997-01-10 1998-01-12 "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"

Country Status (18)

Country Link
EP (1) EP0975351B1 (https=)
JP (1) JP4216342B2 (https=)
KR (1) KR20000070058A (https=)
CN (1) CN100528222C (https=)
AT (1) ATE356608T1 (https=)
AU (1) AU737287B2 (https=)
BR (1) BRPI9807076B8 (https=)
CA (1) CA2277365C (https=)
CZ (1) CZ297983B6 (https=)
DE (1) DE69837324T2 (https=)
EA (1) EA003128B1 (https=)
HU (1) HU226612B1 (https=)
IL (2) IL119989A0 (https=)
NZ (1) NZ336690A (https=)
PL (1) PL193300B1 (https=)
SK (1) SK284029B6 (https=)
WO (1) WO1998030227A1 (https=)
ZA (1) ZA98214B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
JP2003521448A (ja) * 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
EP1187612B1 (en) * 1999-06-04 2005-01-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for the treatment of multiple sclerosis
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
WO2001060392A1 (en) * 2000-02-18 2001-08-23 Yeda Research And Development Co., Ltd. At The Weizmann Institute Of Science Oral, nasal and pulmonary dosage formualtions of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CA2411536A1 (en) * 2000-06-05 2001-12-13 V. Wee Yong The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
SI1459065T1 (sl) 2001-12-04 2010-11-30 Teva Pharma Postopki za merjenje potentnosti glatiramer acetata
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
CA2514125A1 (en) * 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
ES2612001T4 (es) 2009-08-20 2018-02-07 Yeda Research & Development Company, Ltd. Terapia de baja frecuencia con acetato de glatirámero
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
NZ703122A (en) 2010-10-11 2016-06-24 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
KR20140101730A (ko) 2011-10-10 2014-08-20 테바 파마슈티컬 인더스트리즈 리미티드 글라티라머 아세테이트에 대한 임상 반응을 예측하는 데 유용한 단일 뉴클레오티드 다형성
MX2015004563A (es) 2012-10-10 2015-07-14 Teva Pharma Biomarcadores predictivos para respuesta clinica para acetato de glatiramero.
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105884866B (zh) * 2015-01-26 2021-04-20 漳州未名博欣生物医药有限公司 格拉替雷的化学合成方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN112649537B (zh) * 2015-04-28 2024-03-29 深圳翰宇药业股份有限公司 多肽混合物高效液相色谱分析方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
HUE071047T2 (hu) 2016-08-31 2025-07-28 Mapi Pharma Ltd Glatiramer-acetátot tartalmazó depórendszerek
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
JP2020525459A (ja) 2017-06-26 2020-08-27 アンスティテュ・パストゥール Hivリザーバーを排除し、ウイルス負荷を低減する処置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins

Also Published As

Publication number Publication date
CZ297983B6 (cs) 2007-05-16
DE69837324T2 (de) 2007-11-29
ZA98214B (en) 1999-08-11
DE69837324D1 (de) 2007-04-26
CZ243799A3 (cs) 2000-06-14
AU737287B2 (en) 2001-08-16
PL193300B1 (pl) 2007-01-31
BR9807076B1 (pt) 2013-10-29
ATE356608T1 (de) 2007-04-15
SK284029B6 (sk) 2004-08-03
WO1998030227A1 (en) 1998-07-16
PL334566A1 (en) 2000-03-13
HUP0001917A3 (en) 2001-12-28
CN1249690A (zh) 2000-04-05
CA2277365A1 (en) 1998-07-16
NZ336690A (en) 2001-05-25
EA199900621A1 (ru) 2000-02-28
EP0975351A4 (en) 2002-05-15
HU226612B1 (en) 2009-04-28
EP0975351A1 (en) 2000-02-02
EA003128B1 (ru) 2003-02-27
JP2001511121A (ja) 2001-08-07
CN100528222C (zh) 2009-08-19
EP0975351B1 (en) 2007-03-14
KR20000070058A (ko) 2000-11-25
BR9807076A (pt) 2000-05-02
IL119989A0 (en) 1997-04-15
IL130820A (en) 2007-03-08
HK1025737A1 (en) 2000-11-24
HUP0001917A2 (hu) 2000-10-28
SK93199A3 (en) 2000-11-07
JP4216342B2 (ja) 2009-01-28
AU5819598A (en) 1998-08-03
CA2277365C (en) 2011-04-12

Similar Documents

Publication Publication Date Title
BRPI9807076B8 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
RU95110109A (ru) Комплекс, содержащий аналог человеческого инсулина, и фармацевтическая композиция на его основе
FI945912A0 (fi) Proteinoidikantajat ja menetelmät niiden valmistamiseksi sekä niiden käyttö
FR2651677B1 (fr) Composition pharmaceutique a base de salmeterol et du propionate de fluticasone.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
EP1440980A3 (en) Peptide analogs of human myelin basic protein
AU5526899A (en) Bioactive peptides
OA09772A (en) "mometasone furoate monohydrate, process for making same and pharmaceutical compositions".
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
ATE213499T1 (de) Peptidanaloge des menschlichen, basischen myelinproteins mit substitution an position 91 zur behandlung der multiplen sklerose
DK0506772T3 (da) Farmaceutisk præparat indeholdende et phosphosukker
DE60334711D1 (de) Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
KR910002899A (ko) 혈조절 펩타이드
AU7683296A (en) Peptide conjugates derived from thymic hormones, their use as medicament and compositions containing them
WO1996022305A3 (en) Modified peptides
NZ332655A (en) Pharmaceutical compositions containing diclofenac and alkali metal bicarbonates
CA2279184A1 (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
DE3579471D1 (de) Orales dextran enthaltende zusammensetzungen.
GR1002576B (el) Φαρμακευτικες συνθεσεις και μια μεθοδος παρασκευης τους.
GEP20043377B (en) Pharmaceutical Complex
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
AU8452791A (en) 1-phenyl-3-aryl-2-propyne-1-ones
ATE228838T1 (de) Neue n-acetylierte 4-hydroxyphenylaminen derivate mit analgetischen eigenschaften sowie diese enthaltende arzneimittel
DE69902925D1 (de) Ramoplaninhaltige neue injizierbare arzneizubereitungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM O ART. 13 DA LPI 9279/96).

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: DESPACHO: ANULADA A DECISAO DE NEGAR ANUENCIA AO PI ASSINALADO CUJA PUBLICACAO FOI EFETUADA NA RPI 2164 DE 26/06/2012. O PI 9807076-2 DEVERA RETORNAR PARA EXAME TECNICO DE PREVIA ANUENCIA. ESTA ANULACAO TEM COMO BASE A RESOLUCAO- RE NO. 3.255, DE 30/6/2012, PUBLICADA NO DOU EM 31/07/2012.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/10/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/1998 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 12/01/2018

B15V Prolongation of time limit allowed